Flex Corporate Strategy

Flex can accelerate and reduce risk as customers transition to new technology Diabetes monitoring devices $16B $14B $12B $10B BGMs CGMs $8B Hospital Meters $6B $4B $2B $OB 1990 1995 2000 2005 2010 2015 2020 2025 2030 BGM: Blood Glucose Meter | CGM: Continuous Glucose Monitor Flex helps OEMs transition to new innovations with speed and less risk Diagnostics Core laboratory Point of care Dialysis Center based Home care Infusion Hospital-based infusions → Wearable drug delivery devices Patient monitoring Large form factors → Wearable devices Minimally-invasive surgeries Open Laparoscopic Robotic → Endoluminal Source: Market Size: Flex Corporate Strategy Group; 2026 - 2030 CGM Market Size 32 flex

View entire presentation